AI as a Strategic Asset across the MedTech Value Chain

Unlocking the strategic value of AI in MedTech

AI is no longer a future consideration for MedTech. It is being embedded across R&D, manufacturing, commercialisation and regulatory strategy right now. But most companies still have a significant way to go.

Unlocking AI's full potential means confronting real challenges, from cybersecurity vulnerabilities and data governance to a regulatory landscape that varies by region and is still catching up with the pace of innovation. The opportunity is immense — and so is the imperative to get it right.

This new report from Cognizant and Microsoft addresses one of the industry's most pressing questions: how do MedTech companies move from AI experimentation to genuine strategic advantage? Read the report to discover insights from industry experts on how AI can reshape MedTech strategy across the value chain.

“I believe that AI’s ability to minimise human error, increase efficiency and deliver accurate results positions it as a valuable tool in reshaping post-market surveillance.” – Medtech Decision Maker

AI as a Strategic Asset across the MedTech Value Chain

Explore how AI is proving its value across R&D, manufacturing, commercialisation and regulatory strategy, how companies can address the security and governance considerations that come with it, and how the growing wearables / IOT market is beginning to reshape care models entirely. Download our report to find out where the industry stands, and where it needs to go.

Read the report

Discover how AI is transforming the MedTech value chain

Most medtech companies know AI matters. Fewer know how to make it work across the entire value chain. Our latest report explores four interconnected areas where AI is fundamentally changing what’s possible.

R&D

Intelligent processes, including simulation-driven design and predictive failure modelling, compress development timelines and accelerate innovation.

Manufacturing

AI anticipates variation, self-corrects and feeds insights back into design, converging with regulatory-grade process validation to create truly adaptive manufacturing.